黄葵胶囊联合奥美沙坦治疗IgA肾病轻中度蛋白尿临床观察(1)
 |
| 第1页 |
参见附件(2029KB，2页)。
[摘要] 目的 观察黄葵胶囊联合奥美沙坦治疗IgA肾病轻中度蛋白尿的临床疗效。 方法 将60例经肾脏病理活组织检查确诊的IgA肾病患者随机分成两组，各30例，对照组奥美沙坦20 mg，1日1次口服治疗；治疗组黄葵胶囊5粒，1日3次口服，奥美沙坦20 mg，1日1次口服治疗，疗程均为12周，比较两组治疗前后血白蛋白、尿素氮、肌酐、纤维蛋白原(Fib)、24 h尿蛋白定量(UTP)的变化，并判断临床疗效。 结果 治疗12周后，治疗组总有效率(86.7%)明显优于对照组(63.3%)(P < 0.05)，两组治疗后UTP与本组治疗前比较差异有统计学意义(P < 0.05，P < 0.01)，治疗组较对照组降低更显著(P < 0.05)，治疗组Fib较治疗前明显下降(P < 0.05)，与对照组相比差异有统计学意义(P < 0.05)。 结论 黄葵胶囊联合奥美沙坦比单用奥美沙坦能更有效地降低IgA肾病蛋白尿，能降低血纤维蛋白原，副作用少，值得临床推广使用。
[关键词] 黄葵胶囊；奥美沙坦；IgA肾病；蛋白尿
[中图分类号] R692.3 [文献标识码] A [文章编号] 1673-7210(2012)02(c)-0074-02
Clinical study of Huangkui Capsule combined with Olmesartan in the treatment of IgA nephropathy with mild to moderate proteinuria
LI Liusheng YAN Cuiping ZHOU Zhihua
Department of Nephrology, the First People's Hospital of Yichang City People's Hospital of China Three Gorges University, Hubei Province, Yichang 443000, China
[Abstract] Objective To observe the clinical efficacy of Huangkui Capsule combined with Olmesartan in the treatment of IgA nephropathy with mild to moderate proteinuria. Methods Sixty patients with IgA nephropathy proved by biopsy were randomly divided into treatment group and control group, each group contained 30 cases. The treatment group was treated with Huangkui Capsule (5 pills, three times a day) and Olmesartan (20 mg, once a day) for 12 weeks, while the control group was treated with Olmesartan (20 mg, once a day). The changes of serum albumin、blood urea nitrogen、serum creatinine、fibrinogen (Fib) and 24 hours urinary total protein (UTP) in two groups were respectively compared before and after treatment. Results In 12 weeks after treatment, the treatment group total effective rate (86.7%) was higher than the control group (63.3%) (P < 0.05). UTP decreased significantly in two groups (P < 0.05, P < 0.01) and more significantly in treatment group than in control group (P < 0.05). Meanwhile the level of Fib declined greatly (P < 0 ......
您现在查看是摘要介绍页，详见PDF附件(2029KB，2页)。